Evaxion Biotech A/S (EVAX) Stock Forecast
EVAX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.75 / 5 from 4 analysts
- Price target
- $11.25 average of analyst targets
- Upside to target
- +297.5% from the latest close
- Next earnings
- November 19, 2026
- 52-week range
- $2.76 – $7.09
EVAX analyst ratings
4 analystsNumber of analysts at each rating.
EVAX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
EVAX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.01 | −$0.01 | −$0.01 | $0.01 | −200.0% | 1 |
| Current fiscal year (2026) | −$0.04 | −$0.04 | −$0.04 | −$0.02 | −100.0% | 2 |
| Next fiscal year (2027) | −$0.01 | −$0.03 | $0.00 | −$0.04 | +62.5% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
EVAX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | −100.0% | 3 |
| Current fiscal year (2026) | $0 | $0 | $0 | −100.0% | 4 |
| Next fiscal year (2027) | $4.7M | $0 | $18.7M | 0.0% | 4 |
EVAX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
EVAX revenue: reported and forecast
EVAX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.01 | −$0.01 | −$0.01 | −$0.01 | −$0.01 | 0.0% | 0 up · 0 down |
| Current fiscal year (2026) | −$0.04 | −$0.04 | −$0.04 | −$0.04 | −$0.04 | 0.0% | 0 up · 0 down |
| Next fiscal year (2027) | $0.04 | $0.04 | $0.04 | $0.04 | −$0.01 | −137.5% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
EVAX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; EVAX beat in 8 of 12.
What analysts expect from EVAX
4 analysts cover Evaxion Biotech A/S; their consensus rating is strong buy (4.75 on a 1–5 scale, where 5 is a strong buy). The average price target is $11.25, 297.5% above the latest close of $2.83. Analysts expect earnings of −$0.04 per share for 2026, −100.0% from a year earlier. For 2027 the average estimate is −$0.01 per share on revenue of $4.7 million. Evaxion Biotech A/S beat the EPS estimate in 8 of the last 12 quarters.
Related: EVAX income statement, EVAX key metrics, EVAX chart. See the EVAX stock overview for the latest quote and news.
EVAX forecast FAQ
What is Evaxion Biotech A/S's price target?
The average analyst price target for Evaxion Biotech A/S is $11.25, 297.5% above the latest close of $2.83.
Is Evaxion Biotech A/S a buy, hold or sell?
Of 4 analysts covering Evaxion Biotech A/S, 3 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Evaxion Biotech A/S's EPS forecast?
Analysts forecast −$0.04 per share for 2026 (range −$0.04 to −$0.04); for 2027 the estimate is −$0.01.
When does Evaxion Biotech A/S report earnings?
Evaxion Biotech A/S is expected to report results for the quarter ending September 30, 2026 on November 19, 2026 before the market opens.
Does Evaxion Biotech A/S usually beat earnings estimates?
Evaxion Biotech A/S reported EPS at or above the analyst estimate in 8 of the last 12 quarters.